Tuesday’s Daily Piece: Dapagliflozin Continues with More Benefits in Heart Failure

Dapagliflozin is a game changer as this medication addresses renal and cardiovascular protection even in folks without diabetes. In this most recent study (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure [DAPA-HF], the safety and efficacy of dapagliflozin 10 mg vs placebo in a randomized, double-blind, placebo-controlled trial of patients heart failure (HFrEF) was evaluated with primary outcome of the composite of an episode of worsening HR or cardiovascular death. The association found in this study is promising. To learn more, please click below.

Butt JH, Docherty KF, Petrie MC, et al. Efficacy and safety of dapagliflozin in men and women with heart failure with reduced ejection fraction: a prespecified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial. JAMA Cardiol. Published online March 31, 2021. doi:10.1001/jamacardio.2021.0379

Dapagliflozin quickly lowers risk of heart failure and associated CVA: JAMA
This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#dapagliflozin #heartfailure #benefits

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.